Elevance Health Inc

Latest Results (07.08.2024):

Operating Revenue

Elevance Health Inc. reported operating revenue of $43.2 billion for the second quarter of 2024. This represents a slight decrease of $0.2 billion compared to the same quarter in the previous year. The decline was primarily due to attrition in Medicaid membership, although it was partially offset by higher premium yields and growth in CarelonRx product revenue.

Operating Gain

In the second quarter of 2024, Elevance Health Inc. achieved an adjusted operating gain of $2.8 billion. This performance underscores the company's ability to manage costs effectively and maintain profitability despite challenges in the Medicaid segment. The operating gain remained stable compared to the prior year.

Earnings Per Share

Elevance Health Inc. reported a diluted earnings per share (EPS) of $9.85 for the second quarter of 2024, marking a 26% increase from the previous year. The adjusted diluted EPS was $10.12, reflecting a 12% rise. These figures highlight the company's strong earnings performance and effective cost management strategies.

Dividend Declaration

On July 16, 2024, Elevance Health Inc. declared a third-quarter dividend of $1.63 per share. This dividend is payable on September 25, 2024, to shareholders of record as of September 10, 2024. The declaration of this dividend demonstrates the company's commitment to returning value to its shareholders.

Full-Year Outlook

Elevance Health Inc. has maintained its full-year outlook for 2024, expecting GAAP net income per diluted share to be at least $34.05 and adjusted diluted net income per share to be at least $37.20. This outlook reflects the company's confidence in its strategic initiatives and the earnings power of its Health Benefits and Carelon businesses.